CRDF
Price
$2.13
Change
+$0.09 (+4.41%)
Updated
Dec 3 closing price
Capitalization
143.48M
84 days until earnings call
Intraday BUY SELL Signals
XFOR
Price
$3.25
Change
+$0.06 (+1.88%)
Updated
Dec 3 closing price
Capitalization
284.17M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRDF vs XFOR

Header iconCRDF vs XFOR Comparison
Open Charts CRDF vs XFORBanner chart's image
Cardiff Oncology
Price$2.13
Change+$0.09 (+4.41%)
Volume$837.66K
Capitalization143.48M
X4 Pharmaceuticals
Price$3.25
Change+$0.06 (+1.88%)
Volume$508.99K
Capitalization284.17M
CRDF vs XFOR Comparison Chart in %
CRDF
Daily Signal:
Gain/Loss:
XFOR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRDF vs. XFOR commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a StrongBuy and XFOR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (CRDF: $2.04 vs. XFOR: $3.19)
Brand notoriety: CRDF and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 74% vs. XFOR: 48%
Market capitalization -- CRDF: $143.48M vs. XFOR: $284.17M
CRDF [@Biotechnology] is valued at $143.48M. XFOR’s [@Biotechnology] market capitalization is $284.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileXFOR’s FA Score has 0 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • XFOR’s FA Score: 0 green, 5 red.
According to our system of comparison, XFOR is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 6 TA indicator(s) are bullish while XFOR’s TA Score has 2 bullish TA indicator(s).

  • CRDF’s TA Score: 6 bullish, 4 bearish.
  • XFOR’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than XFOR.

Price Growth

CRDF (@Biotechnology) experienced а -3.32% price change this week, while XFOR (@Biotechnology) price change was -15.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

CRDF is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XFOR($284M) has a higher market cap than CRDF($143M). CRDF YTD gains are higher at: -52.995 vs. XFOR (-85.483). CRDF has higher annual earnings (EBITDA): -53.95M vs. XFOR (-91.11M). CRDF has more cash in the bank: 71M vs. XFOR (63M). CRDF has less debt than XFOR: CRDF (1.19M) vs XFOR (78M). XFOR has higher revenues than CRDF: XFOR (32.8M) vs CRDF (545K).
CRDFXFORCRDF / XFOR
Capitalization143M284M50%
EBITDA-53.95M-91.11M59%
Gain YTD-52.995-85.48362%
P/E RatioN/A0.71-
Revenue545K32.8M2%
Total Cash71M63M113%
Total Debt1.19M78M2%
FUNDAMENTALS RATINGS
CRDF vs XFOR: Fundamental Ratings
CRDF
XFOR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6163
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XFOR's Valuation (39) in the Biotechnology industry is in the same range as CRDF (55) in the null industry. This means that XFOR’s stock grew similarly to CRDF’s over the last 12 months.

XFOR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRDF (100) in the null industry. This means that XFOR’s stock grew similarly to CRDF’s over the last 12 months.

CRDF's SMR Rating (98) in the null industry is in the same range as XFOR (99) in the Biotechnology industry. This means that CRDF’s stock grew similarly to XFOR’s over the last 12 months.

CRDF's Price Growth Rating (61) in the null industry is in the same range as XFOR (63) in the Biotechnology industry. This means that CRDF’s stock grew similarly to XFOR’s over the last 12 months.

CRDF's P/E Growth Rating (100) in the null industry is in the same range as XFOR (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to XFOR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFXFOR
RSI
ODDS (%)
Bullish Trend 7 days ago
82%
Bearish Trend 7 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
Momentum
ODDS (%)
Bullish Trend 7 days ago
80%
Bearish Trend 7 days ago
90%
MACD
ODDS (%)
Bullish Trend 7 days ago
80%
Bearish Trend 7 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
85%
Bearish Trend 7 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 7 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
86%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 15 days ago
87%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
89%
N/A
Aroon
ODDS (%)
Bearish Trend 7 days ago
89%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRDF
Daily Signal:
Gain/Loss:
XFOR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARHUF27.50N/A
N/A
AAK AB
PBCRF0.55N/A
N/A
PT Bank Central Asia
PFLC12.00N/A
N/A
Pacific Financial Corp.
QMCI0.14N/A
N/A
QuoteMedia, Inc.
OVHFF9.76N/A
N/A
OVH GROUPE

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with NAMS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-5.99%
NAMS - CRDF
47%
Loosely correlated
-3.23%
ORMP - CRDF
39%
Loosely correlated
+0.36%
NRIX - CRDF
37%
Loosely correlated
-3.31%
ABSI - CRDF
37%
Loosely correlated
+0.16%
SYRE - CRDF
35%
Loosely correlated
-0.91%
More

XFOR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with XCUR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then XCUR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XFOR
1D Price
Change %
XFOR100%
+1.43%
XCUR - XFOR
34%
Loosely correlated
+1.30%
SPHDF - XFOR
34%
Loosely correlated
N/A
CLDX - XFOR
33%
Loosely correlated
+2.85%
CRDF - XFOR
32%
Poorly correlated
-5.99%
MRVI - XFOR
29%
Poorly correlated
+1.78%
More